Latest news
Health Canada review path for PrimeC: NeuroSense (NASDAQ: NRSN) - Stock TitanStock Titan · Thu, 06 Aug 2026 15:56:23 GMTMore than 3,000 Canadians live with ALS; PrimeC filing targets Dec. 2026 - Stock TitanStock Titan · Thu, 06 Aug 2026 15:29:00 GMTNeuroSense Therapeutics Ltd. SEC Filing (Aug 3, 2026) - Stock TitanStock Titan · Mon, 03 Aug 2026 10:13:46 GMTNeuroSense Therapeutics (NRSN) seeks reverse split amid Nasdaq compliance push - Stock TitanStock Titan · Fri, 31 Jul 2026 20:16:46 GMTNeuroSense Therapeutics (NRSN) revises Capital on Demand share sales deal - Stock TitanStock Titan · Fri, 31 Jul 2026 20:16:21 GMTNeuroSense Therapeutics (NRSN) Plunges 14% – Testing Critical Support at $0.46 - Hull Moving Average - dars.gov.etdars.gov.et · Wed, 29 Jul 2026 07:00:00 GMTNeuroSense Therapeutics (NRSN) Plunges 14% – Testing Critical Support at $0.46 - Fibonacci Entry Signals - dars.gov.etdars.gov.et · Wed, 29 Jul 2026 07:00:00 GMTNeurosense Therapeutics Ltd - TradingKeyTradingKey · Mon, 27 Jul 2026 12:13:37 GMT